Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

500 kids tracked daily to unlock secrets of winter viruses

NCT ID NCT06640387

Knowledge-focused Sponsor: The Hospital for Sick Children Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing This study
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study follows 500 children under 18 who tested positive for flu, RSV, or COVID-19. Each child takes a daily nose swab for 14 days to measure how the virus levels change over time. Researchers also check if family members get sick. The goal is to understand when kids are most contagious and how these viruses spread at home and school, which could lead to smarter quarantine rules.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

What this could lead to
If successful, this could provide better guidelines on when children with respiratory infections are contagious, helping schools and families reduce spread.
What could go wrong
This is an observational study, not a treatment trial. It won't directly cure or prevent illness, and results may not apply to all settings or future virus strains.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

About 500 people

The number the study aims to enrol. It can still change while the study runs.

Started

Oct 2024

Expected to finish

May 2027

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Individuals with acute symptomatic influenza, RSV, SARS-CoV-2, mycoplasma pneumoniae, or bordetella pertussis infection identified through hospital testing (inpatient, outpatient, staff household members) or the school-based take-home saliva testing program.

Ages

1 day and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: Viral dynamics (primary outcome): * The child must be less than 18 years of age * Have a positive PCR sample for influenza, RSV or SARS-CoV-2, * Have any one of the symptoms listed to meet testing eligibility: fever, cough, shortness of breath, decreased or loss of taste or smell, muscle aches/joint pains (unusual, long lasting, not related to injury), extreme tiredness (unusual fatigue not otherwise explained), sore throat, runny or stuffy/congested nose, headache (new, unusual, long-lasting), nausea/vomiting and/or diarrhea, and * Be within 5 days of symptom onset Household testing inclusion criteria (secondary outcome): -Any individual in the same household (i.e. household contacts, defined as residing at the same address) as the individual testing positive by PCR for influenza, RSV, SARS-CoV-2, mycoplasma pneumoniae, or bordetella pertussis Classroom testing inclusion criteria (secondary outcome): -Any individual in the same classroom (i.e. classroom contacts) as the individual testing positive by PCR for influenza, RSV, SARS-CoV-2, mycoplasma pneumoniae, or bordetella pertussis (i.e. case identified through the THS program) Exclusion Criteria: Viral dynamics (primary outcome): -Participants will be ineligible if they are more than 5 days from symptom onset

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Bordetella pertussis, whooping cough are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

COVID-19 influenza Mycoplasma pneumoniae pneumonia Mycoplasmoides infection pertussis respiratory syncytial virus infectious disease

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Bordetella pertussis, whooping cough Influenza Mycoplasma pneumoniae RSV infection SARS-CoV-2 infection

Contacts and locations

Locations

  • The Hospital for Sick Children (SickKids)

    Toronto, Ontario, M5G 1X8, Canada

More trials for these conditions

Other studies related to the condition(s) this trial covers.